Share This! Tweet This! Recommend Us! Print Page
Language

Current Cancer Trials

Find a Doctor
Find a Location

Participate in One of These Clinical Trials

Brain

None at this time

ALLIANCE A071102

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Protocol Summary

Consent Form (Screening) - Password Protected

Consent Form (Treatment) - Password Protected

ALLIANCE A221101

A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma

Protocol Summary

Consent Form - Password Protected

NRG-BN001

Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma

Protocol Summary

Consent Form - Password Protected


Breast

NRG-BR003

(This study is also for Node Positive, ER/PR-, HER2- Invasive breast cancer)

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Protocol Summary

Consent Form - Password Protected

NSABP B-55

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

Protocol Summary

Consent Form (Pre Entry - unknown BRCA Status) - Password Protected

Consent Form (Treatment) - Password Protected

-None at this time-

8093

Phase II Trial of Metronomic Eribulin (Halaven) In Pretreated Metastatic Breast Cancer (MBC)

Protocol Summary

SWOG 1207

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy

Protocol Summary

Consent Form - Password Protected

ALLIANCE A011203

A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer

Protocol Summary

Consent Form - Password Protected

NSABP B-51

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Protocol Summary

Consent Form - Password Protected

Alliance A011202

A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Protocol Summary

Consent Form - Password Protected

-None at this time-

Gastrointestinal

SWOG 0820

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III- Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)

Protocol Summary

Consent Form - Password Protected

-None at this time-

PCYC-1137-CA

A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 2/3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma

Protocol Summary

RTOG 0848

A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.

Protocol Summary

Consent Form - Password Protected

ALLIANCE N1048

Quality of Life component is now complete

A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

Protocol Summary

Consent Form - Password Protected

Genitourinary

ALLIANCE A031201

Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer

Protocol Summary

Consent Form - Password Protected

SWOG 1216

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer

Protocol Summary

Consent Form - Password Protected

S0931

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Protocol Summary

Consent Form - Password Protected

ECOG 2810 

Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy

Protocol Summary

Consent Form - Password Protected

Gynecologic

NRG GY006

A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer

Protocol Summary

Consent Form - Password Protected

GOG 0263

Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy

Protocol Summary

Consent Form - Password Protected

RTOG 0724

Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy.

Protocol Summary

Consent Form - Password Protected

-None at this time-

GOG 0277

A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High Grade Uterine Leiomyosarcoma

Protocol Summary

Consent Form - Password Protected

GOG 0281 

A Randomized Phase II/III Study to Assess The Efficacy of Trametinib (GSK 1120212) In Patients With Recurrent Or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer

Protocol Summary

Consent Form - Password Protected

E1Q11 

EROS: Engendering Reproductive Health Within Oncologic Survivorship

Protocol Summary

Consent Form (Main) - Password Protected

Consent Form (Provider) - Password Protected

GOG 0225

Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?

Protocol Summary

Consent Form - Password Protected

Head & Neck

NRG-HN002

A Randomized Phase II Trial for Patients With p16 Positive, Non-smoking Associated, Locoregionally Advanced Oropharyngeal Cancer

Protocol Summary

Consent Form - Password Protected


Hematology

PCYC-1134 M

informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia

Protocol Summary

ECOG 1912

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

Protocol Summary

Consent Form - Password Protected

Patient FAQ - Password Protected

Patient Study Summary - Password Protected

INCB-MA-PV-401:  PRospective ObsErvational Study of Patients with Polycythemia VEra in US ClinicAL Practices (REVEAL)

Protocol Summary

Lung

ALLIANCE A151216

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Protocol Summary

Consent Form - Password Protected

ALLIANCE A081105 

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Protocol Summary

Consent Form - Password Protected

Patient Handout

ECOG 4512

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Protocol Summary

Consent Form - Password Protected

GO29527

A Phase III, Open-label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-based Chemotherapy in PD-L1-Selected Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer

Protocol Summary

GO29436

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Protocol Summary

SCCA 7755 

A Phase II study of weekly Abraxane (nab-paclitaxel) for patients with advanced NSCLC with EGFR mutations following front-line therapy with EGFR tyrosine kinase inhibitors

Protocol Summary

SWOG 1400 (LUNG-MAP)

-Note:  Sub-Studies A and E are permanently closed to accrual-

Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer

Protocol Summary

Consent Form (Pre-Screening) - Password Protected

Consent Form (Screening) - Password Protected

Consent Form (Sub-Study B) - Password Protected

Consent Form (Sub-Study C) - Password Protected

Consent Form (Sub-Study D) - Password Protected

Consent Form (Sub-Study I) - Password Protected

Patient Handout (Ver 12-16-15)

Patient Q and A (Ver 12-16-15)


Lymphoma

None at this time

Melanoma

EA6134 

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

Protocol Summary

Consent Form - Password Protected

SWOG 1320

A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma

Protocol Summary

Consent Form - Password Protected

Multiple Myeloma

E3A06

Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma

Protocol Summary

Other

NCI 9846

-Note:  Open to Virginia Mason Medical Center sites only-

Patient-derived Models Tissue Procurement Protocol for the National Cancer Institute (P9846)

Consent Form - Password Protected

NCI 9671

Exceptional Responders Pilot study:  Molecular profiling of tumors from cancer patients who are Exceptional Responders

Protocol Summary

Consent Form - Password Protected

URCC 13059 (GAP 70+)

A Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy for Advanced Cancer:  Reducing Chemotherapy Toxicity in Older Adults

Protocol Summary

Consent Form (Main) - Password Protected

Physician Information Sheet (if not available online) - Password Protected

URCC 13070 (COACH)

Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers

Protocol Summary

Consent Form (Main) - Password Protected

Consent Form (Caregiver) - Password Protected

Physician Information Sheet (if not available online) - Password Protected


For more information and/or copies of protocols:

Contact Michelle Maxin-Wells by phone at 253-403-7193, or by email: michelle.maxin-wells@multicare.org